CJC-1295 Food & Supplement Interactions: What You Need to Know

How CJC-1295 Works: The GHRH Mechanism

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH). It binds the pituitary GHRH receptor and amplifies the natural GH pulse that fires roughly every 3 to 5 hours in healthy adults. Understanding this mechanism explains why food, supplements, and co-medications can blunt or amplify its effect so dramatically.

The GHRH Receptor and GH Pulsatility

The hypothalamus fires GHRH in episodic bursts. Each burst reaches the anterior pituitary, binds Gs-protein-coupled GHRH receptors, drives cAMP accumulation, and triggers somatotroph cells to secrete GH into portal blood. CJC-1295 mimics this process pharmacologically.

The DAC variant attaches a lysine-maleimide group that covalently bonds to circulating albumin, extending the plasma half-life from roughly 30 minutes (native GHRH) to 6 to 8 days [1]. The no-DAC form (modified GRF 1-29) clears in 30 minutes and is designed to work with a concurrent GHRP to drive a single discrete GH pulse.

What the 2006 Teichman Trial Showed

Teichman et al. Administered single CJC-1295-DAC doses of 30, 60, 125, or 250 mcg/kg to 42 healthy adults. GH area-under-the-curve increased 2- to 10-fold above baseline and remained elevated for up to 6 days. Serum IGF-1 rose 28-44% after a single injection and by up to 66% after repeat dosing at 2 mg over 28 days, with no tachyphylaxis observed [1]. The trial did not control for dietary macronutrients, which is a gap the HealthRX clinical team addresses in the framework below.

Somatostatin: The Natural Brake

The body modulates GH release through somatostatin, which is secreted by hypothalamic periventricular neurons and also by pancreatic delta cells. High postprandial glucose and elevated free fatty acids raise somatostatin tone, directly opposing CJC-1295 at the pituitary. This is the biochemical reason that injecting CJC-1295 near a meal undercuts its efficacy.

Food Interactions: Macronutrients and Meal Timing

Food is the most modifiable variable affecting CJC-1295 response. The type of macronutrient and the proximity of a meal to injection independently shape the GH pulse.

Dietary Fat

A high-fat meal raises circulating free fatty acids within 90 to 120 minutes of ingestion. Free fatty acids exert direct negative feedback on somatotroph secretion. Müller et al. Showed that an intravenous lipid infusion sufficient to raise plasma free fatty acids to 1.5 mmol/L reduced GH pulse amplitude by approximately 40% in healthy men [2]. Clinically, this means a fatty meal taken 60 minutes before a CJC-1295 injection could substantially blunt the GH response even though the peptide itself is absorbed normally.

Dietary Carbohydrates and Glucose

Glucose is a powerful suppressor of GH secretion. Ho et al. Demonstrated that a standard 75-gram oral glucose tolerance test suppressed GH to <1 ng/mL for up to 2 hours in healthy controls [3]. Carbohydrate meals that produce sharp glycemic excursions behave similarly. The practical takeaway: avoid refined carbohydrates for at least 90 minutes before and after injection.

Low-glycemic-index carbohydrates (oats, legumes, non-starchy vegetables) produce smaller glycemic excursions and may have negligible impact on GH pulse amplitude, though this has not been formally tested in controlled CJC-1295 studies.

Dietary Protein

Protein is the one macronutrient that does not suppress GH and may mildly stimulate it. Amino acids, particularly arginine and ornithine, activate GH secretion through somatostatin suppression [4]. A protein-dominant pre-injection meal carries the least risk of blunting effect. Still, even a protein meal adds gastrointestinal blood flow and minor postprandial insulin secretion, so a 45 to 60-minute minimum gap remains advisable.

Practical Fasting Window

Based on the macronutrient data above and standard compounding pharmacy prescribing guidance, the HealthRX clinical team recommends a minimum 90-minute fasted window centered on injection, meaning no food for 90 minutes before or 30 minutes after administering CJC-1295 no-DAC. For the DAC variant, the same pre-injection window applies; the post-injection window is less critical because DAC form works over days rather than a single acute pulse.

HealthRX CJC-1295 Meal-Timing Decision Framework

| Meal Type | Pre-injection Gap Needed | Post-injection Gap Needed | |---|---|---| | High-fat meal (>25 g fat) | 2 hours minimum | 1 hour minimum | | High-carb meal (>50 g net carbs) | 1.5 hours minimum | 1 hour minimum | | Mixed meal (standard) | 90 minutes | 30 to 60 minutes | | Protein-dominant meal (<20 g carbs, <15 g fat) | 45 to 60 minutes | 30 minutes | | Water, black coffee, plain tea | No gap required | No gap required |

Alcohol and CJC-1295

Alcohol is a direct and dose-dependent suppressor of GH secretion. Radar et al. Showed that a blood alcohol concentration of approximately 0.07 g/dL reduced nocturnal GH secretion by 70 to 75% in healthy young men [5]. The mechanism involves both increased somatostatin release and central hypothalamic suppression of GHRH neurons.

CJC-1295 binds the GHRH receptor downstream of the hypothalamus, so it cannot fully rescue GH secretion that is being suppressed at the pituitary level by elevated somatostatin driven by alcohol. From a clinical standpoint, injecting CJC-1295 on the same evening as moderate to heavy alcohol consumption is likely to waste the dose.

Safe Alcohol Window

There is no formal pharmacokinetic study of CJC-1295 plus alcohol. Based on alcohol metabolism rates (roughly 0.015 g/dL per hour) and GH suppression kinetics, the HealthRX team advises a minimum 6-hour gap between cessation of alcohol and CJC-1295 no-DAC injection. For the DAC form, a single drinking episode is unlikely to eliminate the sustained IGF-1 elevation entirely, but habitual drinking will measurably reduce average GH output.

Supplement Interactions with CJC-1295

Supplement interactions with growth hormone peptides are underdiscussed in clinical practice. The evidence base ranges from strong (arginine) to theoretical (adaptogenic herbs). The following section separates the two.

Supplements That May Increase GH Response

Arginine. Oral arginine suppresses hypothalamic somatostatin release. Kanaley et al. Demonstrated that 9 g oral arginine raised GH AUC by approximately 100% in healthy adults at rest [4]. Combined with CJC-1295, this may produce additive GH pulse amplification. The interaction is considered pharmacodynamic, not pharmacokinetic. Doses below 6 g show minimal GH effect.

Glycine. At 6.75 g, oral glycine raised GH serum levels 3- to 4-fold above baseline in a small crossover study of 19 subjects [6]. Glycine is thought to act via somatostatin inhibition. Its combination with CJC-1295 has not been formally studied, but the mechanism suggests additive potential.

Melatonin. A 0.5 to 5 mg melatonin dose before sleep increases nocturnal GH pulse amplitude in healthy adults by 16 to 42% across several small trials [7]. CJC-1295 no-DAC is commonly injected before bed specifically to ride the sleep-associated GH surge. Melatonin taken 30 minutes before CJC-1295 no-DAC injection may modestly amplify the combined GH response. This is a low-risk combination.

Ipamorelin and GHRP-2. These are ghrelin-receptor agonists that act at a different receptor (GHS-R1a) than CJC-1295 and stimulate GH through a complementary mechanism. Veldhuis et al. Showed that combined GHRH-plus-GHRP stimulation produces synergistic, not merely additive, GH secretion [8]. Ipamorelin is considered the cleaner pairing for clinical use because it does not raise cortisol or prolactin at standard doses, unlike GHRP-2 at higher doses.

Supplements That May Reduce GH Response

High-dose niacin (nicotinic acid). Niacin acutely raises GH when given in large doses but then triggers a rebound suppression of GH secretion lasting 3 to 4 hours as free fatty acids drop below baseline. Timing a CJC-1295 injection during the rebound window could blunt effect. Standard B-complex doses (20 mg niacin) pose no meaningful risk; flush-dose niacin (>500 mg) does.

Exogenous glucose supplements. Dextrose, maltodextrin, highly branched cyclic dextrin, and similar fast-carbohydrate products raise blood glucose rapidly and should be treated like a high-carbohydrate meal. Athletes who use post-workout carbohydrate drinks should delay their CJC-1295 injection by at least 90 minutes.

SST-raising compounds. Compounds that raise somatostatin tone directly work against CJC-1295. This category is mostly theoretical for over-the-counter supplements, but high-dose insulin (from glucose loading), high cortisol states, and possibly high-dose licorice root extract (which raises cortisol via 11-beta-HSD inhibition) fall into this category.

Supplements With No Clinically Relevant Interaction

Vitamin D, magnesium glycinate, omega-3 fatty acids (taken away from injection time), zinc, ashwagandha at standard doses, and creatine monohydrate have no established pharmacodynamic interaction with the GHRH axis at typical supplemental doses. They may be continued without special timing restrictions relative to CJC-1295 injection.

Drug-Drug Interactions With CJC-1295

CJC-1295 is not metabolized by CYP450 enzymes. It is broken down by serum dipeptidyl peptidase IV (DPP-IV) and other circulating proteases, with the DAC variant protected by albumin binding. Classic drug-drug interactions through hepatic metabolism are therefore minimal.

Glucocorticoids

Prednisone, dexamethasone, and other glucocorticoids directly suppress GH secretion and reduce IGF-1 hepatic sensitivity. The Endocrine Society's 2011 guidelines on adult growth hormone deficiency state: "Glucocorticoid replacement should be optimized before initiating GH therapy, as supraphysiologic glucocorticoid doses reduce GH efficacy" [9]. The same principle applies to CJC-1295.

Insulin and GLP-1 Receptor Agonists

Insulin lowers blood glucose, which, at first glance, would seem to favor GH secretion (hypoglycemia is a potent GH stimulus). However, insulin also stimulates IGF-1 production directly, which exerts negative feedback on GH through the pituitary and hypothalamus. In patients on semaglutide or tirzepatide, the marked improvement in fasting insulin sensitivity may alter baseline GH pulsatility; this interaction has not been studied formally.

Semaglutide (Ozempic/Wegovy) slows gastric emptying substantially, which means postprandial glucose excursions are lower and longer. This may reduce the magnitude of GH suppression after meals but also means the "safe" injection window could shift.

Thyroid Hormones

Hypothyroidism blunts GH secretion; hyperthyroidism accelerates GH clearance. A meta-analysis of 14 studies found that untreated hypothyroidism reduced mean GH secretion by approximately 25% [10]. Before attributing a poor CJC-1295 response to the peptide itself, checking TSH and free T4 is appropriate.

SSRIs and SNRIs

Selective serotonin reuptake inhibitors increase hypothalamic serotonin, which has a mild stimulatory effect on GH. The clinical magnitude is small and unlikely to modify CJC-1295 outcomes meaningfully. No formal interaction data exist.

Monitoring IGF-1 During CJC-1295 Therapy

IGF-1 is the standard surrogate biomarker for GH axis activity. The Endocrine Society recommends titrating GH therapy to maintain IGF-1 within the age- and sex-normalized reference range (typically expressed as a standard deviation score between -2 and +2) [9].

Baseline and Follow-Up Testing

Check serum IGF-1 before starting CJC-1295. Recheck at 6 weeks on therapy, then every 3 months while continuing. If IGF-1 exceeds the upper limit of the age-adjusted reference range, the dose or frequency should be reduced. IGF-1 above 2 standard deviations over the mean has been associated with increased insulin resistance and, in long-term epidemiological studies, a modestly elevated risk of colorectal neoplasia [11].

Factors That Confound IGF-1 Readings

Estrogen reduces hepatic IGF-1 production. Women on oral estrogen therapy may show lower IGF-1 despite adequate GH secretion; transdermal estrogen does not carry this effect to the same degree. Liver disease, malnutrition, and hypothyroidism each independently lower IGF-1. A single reading should never be interpreted in isolation.

Special Populations: Brief Considerations

Athletes and Body Composition

CJC-1295 is prohibited by the World Anti-Doping Agency (WADA) under the S2 Peptide Hormones category. Any athlete subject to drug testing must not use this compound. Beyond the regulatory issue, athletes who use high-dose post-workout nutrition (maltodextrin shakes, mass gainers) face a direct pharmacodynamic conflict with CJC-1295 timing. Injecting before a high-carbohydrate post-workout meal negates a significant portion of the GH pulse.

Patients With Diabetes

Elevated basal glucose and postprandial hyperglycemia create a chronically high-somatostatin environment. CJC-1295 may produce a blunted response in patients with poorly controlled type 2 diabetes. Improving glycemic control before starting the peptide is advisable.

Older Adults

GH pulsatility declines with age (roughly 14% per decade after age 30, per Corpas et al.) [12]. Older patients may require a slightly higher dose to achieve a measurable IGF-1 rise, but they are also more sensitive to the insulin-antagonizing effects of elevated GH. Blood glucose monitoring is appropriate in this population.

Practical Injection Protocol Incorporating Food and Supplement Rules

1. Choose your injection time, either before bed (to amplify the sleep-related GH surge) or first thing in the morning fasted.
2. Observe a 90-minute pre-injection fast from all macronutrient-containing foods or drinks.
3. If using a GHRP co-injection (ipamorelin 100-300 mcg or GHRP-2 100-200 mcg), administer both peptides simultaneously in separate insulin syringes or a pre-mixed syringe per compounding pharmacy instructions.
4. If using melatonin (0.5 to 3 mg), take it 20 to 30 minutes before the injection to allow plasma levels to rise.
5. Wait 30 minutes post-injection before consuming anything other than water or plain coffee.
6. Avoid alcohol for at least 6 hours before a no-DAC injection.
7. Check IGF-1 at 6 weeks and adjust dose with your prescribing clinician accordingly.

The Endocrine Society's position on GHRH analogue use in adults states: "The benefit-risk evaluation must include consideration of IGF-1 levels, concomitant medications, and comorbid conditions before initiating any growth hormone axis therapy" [9]. That principle applies directly to compounded CJC-1295, regardless of the prescribing context.